kronos gri q3

Nextleaf Solutions Granted Patent for CBD Prodrug and Prepares for Pharmaceutical Participation

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) ("Nextleaf", "OILS", or the "Company"), the world's most innovative cannabis extractor, announced today that the Canadian Intellectual Property Office has granted the Company a patent for the acetylation of cannabinoids. More specifically, the patent covers a process for acetylating cannabidiol ("CBD"), and subsequent refinement of CBD-O-Acetate using a proprietary extraction and distillation technique.


The Company owns 12 issued U.S. patents and 70 issued patents globally for the extraction, purification, and delivery of cannabinoids - representing the 2nd largest patent portfolio among all cannabis companies.

"We expect the results of the 2020 U.S. elections will have a transformational effect on the commercial value of our U.S. patent portfolio," stated Paul Pedersen, CEO of Nextleaf Solutions. "The world's largest cannabis company launching the industry's first patent infringement lawsuit against GW Pharma on December 22, 2020 demonstrates the value of patents and intellectual property in the cannabis industry."

This patented process to produce CBD-O-Acetate enables the standardization of a more potent analog of CBD through targeted drug delivery. Prodrugs utilize various physical and chemical modifications to improve features of active drugs. Maintaining the integrity of the molecule and its ability to deliver drugs to precisely targeted areas in the body may increase efficacy for desired outcomes.

The Company believes an orally consumable CBD metabolic prodrug produced under its patented process for acetylating cannabidiol will enhance the therapeutic potency of CBD.

OILS already owns U.S. patents for the acetylation of THC, and the acetylation of CBD. The Company's patent portfolio and Health Canada licenses for cannabis processing and research presents an entry point for pharmaceutical firms looking to manufacture cannabinoid prodrugs in a federally legal jurisdiction.

The Company plans to commercialize this intellectual property ("IP") through IP licensing, and the production of IP protected cannabinoid-based products as legally permitted by Health Canada.

Nextleaf has engaged Kronos Capital Partners Inc. ("Kronos") to pursue and evaluate global strategic partners and investors. Kronos is a strategic advisor and an active investor in the global cannabis and life science sectors.

About Nextleaf®

OILS is the world's most innovative cannabis extractor, having developed the 2nd largest portfolio of U.S. patents among all cannabis companies. The Company wholesales THC and CBD oils and provides extraction services through its wholly owned subsidiary Nextleaf Labs Ltd. The Company's automated closed-loop extraction plant in Metro Vancouver has a design capacity to process 600 kg per day of dried cannabis biomass into distilled oils. Nextleaf Labs holds Health Canada licenses for standard processing and research under the Cannabis Act, allowing for a number of licenced activities including sensory evaluation of cannabis via human testing. The Company owns a portfolio of 12 issued U.S. patents, and 70 issued patents globally, for the extraction, purification, and delivery of cannabinoids.

Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.

Follow OILS across social media platforms: Twitter, LinkedIn, Facebook, and Instagram.

www.nextleafsolutions.com

For more information please contact:
Jason McBride
604-283-2301 (ext. 219)
investors@nextleafsolutions.com

On behalf of the Board of Directors of the Company,

Paul Pedersen, CEO

Certain statements contained in this press release constitute "forward-looking statements". All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company's ability to capitalize on its IP portfolio,the Company's strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company's MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed or approved the contents of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72247

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Person touching a cannabis plant; Australia map in flag colours.

ASX Cannabis Stocks: 10 Biggest Companies in 2024

While Australia has yet to legalise all forms of cannabis, the country is a growing medical cannabis and hemp market, with many companies manufacturing, researching and exporting the plant-based product.

Medical cannabis was federally legalised in 2016, and the export of cannabis from Australia was legalised in 2018. The only state to legalise recreational use so far is the Australian Capital Territory, which did so in 2020; however, recreational cannabis is not available for purchase in the state and must be grown by the user, meaning the legislation is quite restrictive.

The country's medical cannabis market has been steadily expanding in size and scope. In fact, a 2021 survey of 1,600 medical cannabis users shows that 37 percent of respondents were using legally prescribed cannabis compared to just 2.7 percent of respondents in 2018. More recently, a 2023 survey showed that 50 percent of Australians supported legalising the right to own six personal cannabis plants, with only 31 percent of those surveyed opposing such a law.

Australian cannabis companies listed on the ASX are operating in this space, creating products such as medicines, flower and hemp products; there are also ASX-listed cannabis companies producing recreational cannabis in other countries.

Keep reading...Show less

Trulieve Announces Upcoming Event Participation

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced planned event participation.

Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)

  • ATB Capital Markets 2024 Life Sciences Institutional Investor Conference, September 18, 2024 : Vice President of Investor Relations Christine Hersey will participate in investor meetings.
  • Benzinga Cannabis Capital Conference, October 8 - 9, 2024 : Chief Marketing Officer Gina Collins will participate in a panel discussion on Next-Gen Cannabis Retail on October 9th at 11:00 AM , and Vice President of Investor Relations Christine Hersey will participate in a VIP Roundtable discussion on Capital Markets and investor meetings.

Information about our events, links to events where available, and slide presentations can be found at: https://investors.trulieve.com/events

About Trulieve

Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.

Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve

Investor Contact  
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact  
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-announces-upcoming-event-participation-302245660.html

SOURCE Trulieve Cannabis Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2024/12/c1444.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve to Open Medical Cannabis Dispensary in Clearwater, Florida

New Pinellas County location will host grand opening celebration Friday, September 13 th

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., announced the opening of a new medical cannabis dispensary in Clearwater, Florida on Saturday, September 7 .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Opens Relocated Dispensary in Tucson, Arizona

New Menlo Park location to celebrate grand opening Friday, September 13 th

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the relocation of a dispensary in Tucson, Arizona .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Cannabis leaves, US flag.

Cannabis Round-Up: US Sets Date for Hearing on Rescheduling, State Markets See Growth

August brought a whirlwind of activity in the cannabis industry as the US Drug Enforcement Administration (DEA) set a date for a long-awaited public hearing on the rescheduling of cannabis.

According to public records, the hearing will commence on December 2, 2024, in Arlington, Virginia.

While this date delays the process until after the election, it is still possible that cannabis will be rescheduled before current President Joe Biden leaves office on January 25, 2025.

Keep reading...Show less

Trulieve to Open Florida Medical Cannabis Dispensaries in Cocoa, Miramar Beach, Niceville, and Tampa

Grand opening celebrations at all four locations Friday, September 6 th

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., announced the opening of new medical cannabis dispensaries in Miramar Beach Niceville and Tampa today and Cocoa on Saturday.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×